Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Teva
Boehringer Ingelheim
Cerilliant
McKinsey
QuintilesIMS
Healthtrust
Chubb
McKesson

Generated: December 12, 2018

DrugPatentWatch Database Preview

VYZULTA Drug Profile

« Back to Dashboard

When do Vyzulta patents expire, and when can generic versions of Vyzulta launch?

Vyzulta is a drug marketed by Bausch And Lomb and is included in one NDA. There are five patents protecting this drug.

This drug has sixty-nine patent family members in forty countries.

The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this compound. Additional details are available on the latanoprostene bunod profile page.

Summary for VYZULTA
International Patents:69
US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 2
Patent Applications: 5
Drug Prices: Drug price information for VYZULTA
DailyMed Link:VYZULTA at DailyMed
Drug patent expirations by year for VYZULTA
Generic Entry Opportunity Date for VYZULTA
Generic Entry Date for VYZULTA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION/DROPS;OPHTHALMIC

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Synonyms for VYZULTA
4-(Nitrooxy)butyl (5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)hept-5-enoate
4-nitrooxybutyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
860005-21-6
BOL-303259-X
BOL-303259-X1
CHEMBL2364612
D05LQX
D10441
DB11660
GTPL9635
I6393O0922
Latanoprostene BUNOD
Latanoprostene bunod (USAN/INN)
Latanoprostene BUNOD [USAN:INN]
Latanoprostene bunod)
NCX 116
NCX-116
Nitric oxide-donating prostaglandin F2-alpha analogs (eye disease), NicOx/Pfizer
NO donors (glaucoma), NicOx/Pfizer
NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/ Bausch & Lomb
NO-donating prostaglandin F2-alpha analogs (glaucoma), NicOx/Pfizer
NO-donating prostaglandin F2-alpha analogs (glaucoma), Pfizer
PF-03187207
PF-3187207
SCHEMBL12119560
UNII-I6393O0922
Vesneo

US Patents and Regulatory Information for VYZULTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb VYZULTA latanoprostene bunod SOLUTION/DROPS;OPHTHALMIC 207795-001 Nov 2, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Bausch And Lomb VYZULTA latanoprostene bunod SOLUTION/DROPS;OPHTHALMIC 207795-001 Nov 2, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Bausch And Lomb VYZULTA latanoprostene bunod SOLUTION/DROPS;OPHTHALMIC 207795-001 Nov 2, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Dow
Medtronic
Farmers Insurance
Queensland Health
Chubb
McKesson
Covington
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.